MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

NCT ID: NCT02858791

Last Updated: 2018-01-09

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 99 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2017-12-21

Brief Summary

The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.

Detailed Description

The investigators will test our hypothesis and accomplish our objectives by pursuing three Specific Aims:

To investigate the interrelationship between macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH with a working hypothesis that an increased release of MIF into the pulmonary vasculature during cardiopulmonary exercise changes the normal balance between plasma MIF and T4.

Conditions

Pulmonary Hypertension; Pulmonary Arterial Hypertension; Interstitial Lung Disease

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Healthy Controls

Subjects are made up of healthy adults

Interventions:

Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test

No interventions assigned to this group

Affected

Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease

Interventions:

Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Subject must be at least 18 years of age and have confirmed pulmonary hypertension (PH) and interstitial lung disease (ILD).
• ILD was identified on high resolution computed tomography along with a total lung capacity (TLC) <70% of predicted value on pulmonary function tests (PFTs) with no evidence of pulmonary hypertension on echocardiogram.
• PAH group patients were defined as patients with a mean pulmonary artery pressure >25 mmHg at rest and a wedge pressure of <15 mmHg (millimeters of mercury), measured by right heart catheterization (WHO group I PAH).
• PH+ILD group, subjects with evidence of ILD on high resolution CT Scan and mean pulmonary artery pressure >25 mmHg on right heart catheterization.
• Patient with evidence of Chronic thromboembolic disease on CT angiogram and mean pulmonary artery pressure >25mmHg on right heart catheterization. (WHO group IV)
• Patient with Pulmonary Hypertension due to other conditions, such as Sarcoidosis, Gauchers disease, Hemolytic Anemia and Myeloproliferative disorders.
• Normal control group: Subjects without cardiopulmonary disease, with a normal PFT and ECG.

Exclusion Criteria

• Failure to obtain informed consent;
• Pregnancy
• Subjects with cardiopulmonary disease other than PH and ILD;
• Unexplained abnormal PFT, ECG, Routine blood/chemistries test
• History or existing other sever organ/system diseases
• Defined Acute pulmonary embolism
• Age < 18 years

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Northwell Health

OTHER

Sponsor Role: lead

Responsible Party

Arunabh Talwar

Attending Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Northwell Health

New Hyde Park, New York, United States

Countries

United States

Other Identifiers

13-003A

Identifier Type: -

Identifier Source: org_study_id